I think they were blindsided by the FDA. The FDA saw prototypes and must've given no indication of any issues. If they did then surely BOT management would've rectified the problem. They've launched 30 previous products over their careers.
I'm doubting this was due to management incompetence.
Ann: FDA Letter Requires Patient Instruction Update, page-161
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.005(1.35%) |
Mkt cap ! $671.1M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 39.0¢ | 37.0¢ | $771.7K | 2.030M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 201069 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 124279 | 14 |
View Market Depth
| Last trade - 13.17pm 09/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |